UK drug discovery company Summit has signed a technology licensing agreement with US pharmaceuticals colossus, Bristol-Myers Squibb.
The US firm will use use Summit's proprietary Seglin technology to identify and develop drug candidates for up to ten targets across multiple therapeutic areas. Summit will receive a $100,000 technology access fee and is eligible for research, development and regulatory milestones of up to $30m per product, plus royalties on worldwide sales of products arising from the technology.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Eckoh, the provider of speech recognition and associated payment solutions, has been awarded a three year contract with international services company Serco to provide hosted speech recognition services to a client within central government. It is the company's first contract win with Serco, one of the UK's leading outsourcing firms.
JH
-
Millions at risk of 'unnecessary' tax bill – how to shield your savingsMillions of Brits could be taxed on their savings interest this year as their savings interest exceeds the personal savings allowance. Are you at risk?
-
Savers will have to wait as long as 48 years to build a £1m cash ISA pot if allowance is cutChancellor Rachel Reeves is rumoured to be planning a cut to the cash ISA allowance in the Autumn Budget, making it harder for savers to build wealth. Will you still be able to build a £1 million cash ISA pot?
